

Resource Summary Report

Generated by [nidm-terms](#) on Jul 28, 2026

Oncotator

RRID:SCR_005183

Type: Tool

Proper Citation

Oncotator (RRID:SCR_005183)

Resource Information

URL: <http://www.broadinstitute.org/cancer/cga/ncotator>

Proper Citation: Oncotator (RRID:SCR_005183)

Description: A tool for annotating human genomic point mutations and indels with data relevant to cancer researchers. Genomic Annotations, Protein Annotations, and Cancer Annotations are aggregated from many resources. A standalone version of Oncotator is being developed.

Abbreviations: Oncotator

Resource Type: analysis service resource, service resource, data analysis service, production service resource

Keywords: annotate, genomic, point mutation, indel, mutation, genome, protein, variant

Related Condition: Cancer

Resource Name: Oncotator

Resource ID: SCR_005183

Alternate IDs: OMICS_00178

Record Creation Time: 20220129T080228+0000

Record Last Update: 20260728T043213+0000

Ratings and Alerts

No rating or validation information has been found for Oncotator.

No alerts have been found for Oncotator.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 215 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. Cell reports. Medicine, 6(2), 101929.

Ghosh A, et al. (2025) Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours. Communications biology, 8(1), 207.

Kübler K, et al. (2025) Tamoxifen induces PI3K activation in uterine cancer. Nature genetics, 57(9), 2192.

Liu Z, et al. (2025) Illuminating the FGFR fusion landscape in Chinese patients: unveiling novel molecular insights and clinical implications. The oncologist, 30(11).

Zhong S, et al. (2025) Genomic landscape and immunological profile of glioblastoma in East Asian patients. Cell reports. Medicine, 6(8), 102217.

Zhang X, et al. (2025) Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets. Nature communications, 16(1), 4398.

Sun W, et al. (2025) A mutational process signature and genomic alterations associated with outcome and immunogenicity in cancers with brain metastasis. Frontiers in immunology, 16, 1607772.

Yang Q, et al. (2025) Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function. Scientific reports, 15(1), 8437.

Feng EM, et al. (2025) Racial variation in the advanced prostate cancer genome. Prostate cancer and prostatic diseases, 28(4), 902.

Wu M, et al. (2025) Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors. Immunity, 58(11), 2864.

Wang H, et al. (2025) Genome-Wide Association Analysis of Flavor Precursor Traits in Chengkou Mountain Chicken. Animals : an open access journal from MDPI, 15(12).

Lu S, et al. (2025) Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trial. EClinicalMedicine, 84, 103258.

Knight AD, et al. (2025) Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy. medRxiv : the preprint server for health sciences.

Zhang J, et al. (2024) Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer. Signal transduction and targeted therapy, 9(1), 65.

Díaz-Gay M, et al. (2024) The mutagenic forces shaping the genomic landscape of lung cancer in never smokers. medRxiv : the preprint server for health sciences.

Liu X, et al. (2024) Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in Hepatocellular Carcinoma. Nature communications, 15(1), 3169.

Chang Y, et al. (2024) CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II. Briefings in bioinformatics, 26(1).

Choudhury AD, et al. (2024) Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. Cancer immunology research, 12(6), 704.

Czerniak B, et al. (2024) Inferring Bladder Cancer Evolution from Mucosal field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping. Research square.

Zou H, et al. (2024) Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. Journal for immunotherapy of cancer, 12(3).